The progress that ADCETRIS has made becoming a major franchise is remarkable to say the least. Not only are their net sales approaching Phase 3 trial readouts, those designed to support future expansions and revolutionize the way the CD30-Expressing lymphomas are treated, but for the SGN-CD33A, their lead program, has five full ongoing trials!
Promising antitumor activity is arising from many of the programs. Their pipeline is advancing as they prepare for many more clinical trials on more novel programs.
As of July of 2016, ADCETRIS has reached 65 countries. As such their total revenues for the second quarter was 95.4 million dollars, which included record sales of 66.2 million, a 20 percent increase over last year’s second quarter. They are confident that they will indeed reach their estimated goal of 225 million or even as high as 275 million.
Clay Siegall, The founder and CEO of Seattle Genetics, has built that company from the ground up. Starting in 1998, Dr. Siegall has secured funding both privately and publicly to pull Seattle Genetics into one of the leading cancer research centers in the world. Starting from almost nothing with just his PhD in Genetics and his B.S. in Zoology, he has succeeded in bringing the company’s worth to over 600 million dollars in just 18 years, as well as developing a large group of strategic collaborations to help with the development of his company.
Currently Dr. Siegall is the author of over 70 publications and holds as many as 15 different patents. We can only hope for more success coming Dr. Siegall’s was as his company rolls into the third quarter this year.